Skip to main content

Scientist: Andrew Ip

ESMH scientist Andrew IpDoctor Andrew Ip is a specialist in hematology/oncology at the John Theurer Cancer Center at Hackensack University Medical Center, USA. He has been involved in research on tocilizumab use in COVID-19 patients.

Tocilizumab, Coronavirus Covid-19 treatment illustration banner

Tocilizumab : a treatment alternative in COVID-19 pneumonia

Patients with severe COVID-19 pneumonia often need to be mechanically intubated and have an increased mortality risk. Tocilizumab, a drug used against the cytokine storm underlying this clinical condition, has shown positive effects in clinical trials.

Dr Andrew Ip, Coronavirus Covid-19 treatment illustration banner

A scientist’s opinion : Interview with Dr Andrew Ip about covid-19 treatment

Interview with Dr Andrew Ip, a specialist in hematology/oncology at the John Theurer Cancer Center at Hackensack University Medical Center, USA, who has been involved in research on tocilizumab use in COVID-19 patients. Why did you choose tocilizumab to treat patients with COVID-19 pneumonia? Andrew Ip: Tocilizumab is a monoclonal antibody that inhibits the interleukin-6 ...